Summit Creek Advisors LLC Sells 7,586 Shares of Addus HomeCare Corporation $ADUS

Summit Creek Advisors LLC lessened its stake in Addus HomeCare Corporation (NASDAQ:ADUS) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 177,296 shares of the company’s stock after selling 7,586 shares during the quarter. Addus HomeCare makes up approximately 3.0% of Summit Creek Advisors LLC’s holdings, making the stock its 2nd biggest holding. Summit Creek Advisors LLC’s holdings in Addus HomeCare were worth $19,040,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. TimesSquare Capital Management LLC raised its stake in shares of Addus HomeCare by 6.2% in the 3rd quarter. TimesSquare Capital Management LLC now owns 418,348 shares of the company’s stock valued at $49,361,000 after purchasing an additional 24,301 shares in the last quarter. Burney Co. acquired a new stake in shares of Addus HomeCare in the 4th quarter valued at about $1,841,000. Public Sector Pension Investment Board raised its stake in shares of Addus HomeCare by 14.4% in the 3rd quarter. Public Sector Pension Investment Board now owns 70,827 shares of the company’s stock valued at $8,357,000 after purchasing an additional 8,893 shares in the last quarter. Capital Research Global Investors raised its stake in shares of Addus HomeCare by 9.0% in the 3rd quarter. Capital Research Global Investors now owns 1,201,560 shares of the company’s stock valued at $141,772,000 after purchasing an additional 99,262 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Addus HomeCare by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,298,104 shares of the company’s stock valued at $153,163,000 after purchasing an additional 36,674 shares in the last quarter. Institutional investors and hedge funds own 95.35% of the company’s stock.

Addus HomeCare Price Performance

Shares of NASDAQ:ADUS opened at $93.76 on Thursday. The firm’s 50 day moving average is $96.10 and its two-hundred day moving average is $105.73. Addus HomeCare Corporation has a 52 week low of $89.76 and a 52 week high of $124.43. The firm has a market capitalization of $1.75 billion, a P/E ratio of 17.33, a PEG ratio of 1.27 and a beta of 0.92. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.08.

Addus HomeCare (NASDAQ:ADUS) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.52 by $0.10. Addus HomeCare had a net margin of 6.89% and a return on equity of 9.80%. The company had revenue of $363.50 million for the quarter, compared to analyst estimates of $366.41 million. During the same quarter last year, the business earned $1.42 earnings per share. Addus HomeCare’s revenue was up 7.7% compared to the same quarter last year. Analysts anticipate that Addus HomeCare Corporation will post 6.24 earnings per share for the current year.

Analyst Ratings Changes

ADUS has been the topic of a number of recent analyst reports. Barclays cut their target price on shares of Addus HomeCare from $102.00 to $92.00 and set an “underweight” rating on the stock in a research note on Friday, May 15th. KeyCorp reiterated an “overweight” rating on shares of Addus HomeCare in a research note on Wednesday, February 25th. Citizens Jmp reiterated a “market outperform” rating and set a $142.00 price objective on shares of Addus HomeCare in a research note on Monday. Wall Street Zen lowered shares of Addus HomeCare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 21st. Finally, Stephens dropped their price objective on shares of Addus HomeCare from $140.00 to $135.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $131.22.

Insider Buying and Selling

In other Addus HomeCare news, EVP Sean Gaffney sold 442 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $105.36, for a total value of $46,569.12. Following the sale, the executive vice president owned 20,080 shares in the company, valued at approximately $2,115,628.80. This trade represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David W. Tucker sold 379 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $105.36, for a total transaction of $39,931.44. Following the completion of the transaction, the executive vice president owned 10,423 shares of the company’s stock, valued at $1,098,167.28. This trade represents a 3.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 16,788 shares of company stock valued at $1,785,633 in the last ninety days. Insiders own 4.50% of the company’s stock.

Addus HomeCare Profile

Addus HomeCare (NASDAQ: ADUS) is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients’ independence and quality of life.

The company’s core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.